logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

AACR 2020 – mCRPC: no OS benefit with enzalutamide plus atezolizumab

No OS benefits leads to early termination of phase 3 IMbassador250 clinical trial.